Endocrine Abstracts

Introduction: Adrenocortical carcinoma (ACC) is a rare malignant tumor with heterogeneous prognosis. The median overall survival of all ACC patients is about 3-4 years. Complete surgical resection provides the only cure [Fassnacht M, et al., 2018]. In cases of advanced ACC, therapeutic options are limited. No effective second-line therapies are recommended for patients with disease progression to EDP chemotherapy scheme and Mitotane. It is essential to study alternative drugs,...